Donaldson Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.94M Buy
65,027
+3,905
+6% +$228K 0.13% 81
2025
Q4
$3.3M Buy
61,122
+1,900
+3% +$91.4K 0.1% 87
2025
Q3
$2.67M Buy
59,222
+583
+1% +$27.2K 0.08% 96
2025
Q2
$2.71M Sell
58,639
-2,806
-5% -$138K 0.1% 92
2025
Q1
$3.75M Buy
61,445
+2,050
+3% +$119K 0.14% 75
2024
Q4
$3.36M Buy
59,395
+22,653
+62% +$1.27M 0.13% 80
2024
Q3
$1.9M Sell
36,742
-3,655
-9% -$171K 0.07% 109
2024
Q2
$1.68M Sell
40,397
-599,458
-94% -$26.8M 0.07% 108
2024
Q1
$34.7M Buy
639,855
+33,552
+6% +$1.71M 1.44% 31
2023
Q4
$31.1M Sell
606,303
-76,431
-11% -$4.01M 1.39% 32
2023
Q3
$39.6M Buy
682,734
+16,880
+3% +$1.03M 1.87% 24
2023
Q2
$42.6M Buy
665,854
+103,506
+18% +$6.94M 1.94% 25
2023
Q1
$39M Buy
562,348
+510,660
+988% +$36M 1.84% 31
2022
Q4
$3.72M Sell
51,688
-169
-0.3% -$12.7K 0.18% 67
2022
Q3
$3.69M Buy
51,857
+1,614
+3% +$117K 0.2% 65
2022
Q2
$3.87M Buy
50,243
+119
+0.2% +$9.06K 0.2% 64
2022
Q1
$3.66M Buy
50,124
+195
+0.4% +$13.1K 0.17% 69
2021
Q4
$3.11M Sell
49,929
-630
-1% -$37K 0.14% 73
2021
Q3
$2.99M Sell
50,559
-1,335
-3% -$87.9K 0.15% 74
2021
Q2
$3.47M Sell
51,894
-227
-0.4% -$14.8K 0.18% 72
2021
Q1
$3.29M Buy
52,121
+380
+0.7% +$23.6K 0.18% 71
2020
Q4
$3.21M Sell
51,741
-147
-0.3% -$9.04K 0.19% 65
2020
Q3
$3.13M Hold
51,888
0.21% 64
2020
Q2
$3.05M Hold
51,888
0.22% 60
2020
Q1
$2.89M Sell
51,888
-1,703
-3% -$104K 0.25% 54
2019
Q4
$3.44M Buy
53,591
+2,616
+5% +$150K 0.23% 62
2019
Q3
$2.58M Buy
50,975
+42,506
+502% +$2M 0.19% 70
2019
Q2
$384K Sell
8,469
-788
-9% -$36.7K 0.03% 118
2019
Q1
$442K Hold
9,257
0.04% 108
2018
Q4
$481K Sell
9,257
-450
-5% -$24.2K 0.05% 102
2018
Q3
$603K Sell
9,707
-536
-5% -$31.8K 0.05% 106
2018
Q2
$567K Sell
10,243
-711
-6% -$38.4K 0.06% 100
2018
Q1
$693K Sell
10,954
-2,452
-18% -$158K 0.07% 98
2017
Q4
$822K Sell
13,406
-418
-3% -$26.1K 0.08% 92
2017
Q3
$881K Buy
13,824
+162
+1% +$9.46K 0.09% 86
2017
Q2
$761K Sell
13,662
-699
-5% -$38K 0.09% 90
2017
Q1
$781K Sell
14,361
-2,631
-15% -$144K 0.09% 87
2016
Q4
$993K Buy
16,992
+739
+5% +$40.4K 0.12% 80
2016
Q3
$876K Sell
16,253
-3,399
-17% -$218K 0.12% 72
2016
Q2
$1.45M Buy
19,652
+3,263
+20% +$231K 0.2% 58
2016
Q1
$1.05M Sell
16,389
-199
-1% -$12.6K 0.15% 62
2015
Q4
$1.14M Buy
16,588
+1,493
+10% +$98.7K 0.17% 58
2015
Q3
$894K Buy
15,095
+1,772
+13% +$112K 0.13% 66
2015
Q2
$887K Hold
13,323
0.13% 69
2015
Q1
$859K Sell
13,323
-2,294
-15% -$144K 0.12% 69
2014
Q4
$922K Buy
15,617
+3,708
+31% +$209K 0.14% 68
2014
Q3
$609K Sell
11,909
-576
-5% -$28.8K 0.1% 78
2014
Q2
$606K Sell
12,485
-198
-2% -$9.76K 0.1% 79
2014
Q1
$659K Buy
12,683
+601
+5% +$32K 0.12% 67
2013
Q4
$642K Buy
12,082
+150
+1% +$7.64K 0.12% 64
2013
Q3
$552K Sell
11,932
-1,365
-10% -$59.9K 0.12% 64
2013
Q2
$594K Buy
+13,297
New +$577K 0.13% 61

Other funds holding BMY

Donaldson Capital Management's BMY Position: Q1 2026 in Review

Donaldson Capital Management increased its Bristol-Myers Squibb (BMY) stake by 6.4% in Q1 2026, buying an estimated $228K and bringing the position to 65,027 shares worth $3.94M. The position accounts for 0.13% of the portfolio, ranked #81.

Donaldson Capital Management first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $42.6M in Q2 2023. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Donaldson Capital Management held 65,027 shares of Bristol-Myers Squibb worth $3.94M as of Q1 2026.
  • Donaldson Capital Management bought 3,905 Bristol-Myers Squibb shares in Q1 2026, an estimated $228K.
  • Bristol-Myers Squibb made up 0.13% of Donaldson Capital Management's portfolio in Q1 2026, its #81 holding.
  • Donaldson Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Donaldson Capital Management's Bristol-Myers Squibb position peaked at $42.6M in Q2 2023.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Donaldson Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.